The Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are important evaluation tools for assessing psoriasis severity and guiding treatment options. However, the scores of PASI and DLQI are often inconsistent.
The retrospective study was based on 4125 patients. We collected the PASI, DLQI, demographic and clinical characteristics data.
DLQI has a weak correlation with PASI (r=0.37; P<0.001). For the DLQI >10 groups, DLQI has almost no correlation with PASI (r=0.16; P<0.001). There are 43.60% of mild-to-moderate patients (PASI<10) in the DLQI>10 groups. Our adjusted model showed that foot (OR=2.109; 95% CI:1.581–2.815) involvement led to the greatest impairment of QoL except for PASI≥10 (OR=5.547; 95% CI:3.477–8.845). Furthermore, DLQI impairment was associated with female (OR=1.336; 95% CI:1.071–1.667); the age of 20–39 subgroup (OR=1.795; 95% CI:1.100–2.930); psoriatic arthritis (OR=1.718; 95% CI:1.208–2.443); higher income (OR = 1.408; 95% CI: 1.067–1.858); family history of psoriasis (OR=1.460; 95% CI:1.131–1.885). Moreover, the influence of exposed lesions (such as scalp; face; neck; nails; and hands) were positively associated with severely impaired QoL.